Introduction
The physiological actions of thyroid hormones are mediated by nuclear receptors (thyroid receptor [TR]α and TRβ) encoded by separate genes (THRA and THRB), which regulate gene expression in target tissues. TRs bind to DNA usually as a heterodimer with retinoid X receptor. When not bound to thyroid hormone, TR binds to the promoters of thyroid hormone-target genes-within gene promoter regions known as thyroid response elementsin complex with multiprotein corepressor complexes, inhibiting gene transcription. When thyroid hormone binds to a TR, a conformational change leads to dissociation of corepressor proteins and coactivator proteins can associate with the receptor, leading to transcriptional activation of target genes. 1 Alternative splicing of the THRA transcript generates two subtypes of TRα with identical aminoterminal and DNA-binding domains, but diff erent carboxyterminal regions. Because of this diff erence, TRα1 binds thyroid hormone. By contrast, TRα2 does not bind thyroid hormone but does bind DNA. TRα1 is most highly expressed in myocardium, skeletal muscle, the gastrointestinal tract, and the CNS; some forms of TRα1 that are truncated at the aminoterminus are expressed in mitochondria, aff ecting its function. 2, 3 TRα2 is widely expressed, but its function is not understood. 3 The incidence of resistance to thyroid hormone mediated by defective TRβ is roughly 1 in 40 000 people, and several hundred heterozygous mutations in THRB gene (most within three hotspots in the thyroid hormonebinding domain) have been identifi ed in people with this disorder. 4 Consistent with the dominant inheritance pattern observed for this disorder, mutant TRβ proteins inhibit the function of their normal counterparts in a dominant-negative manner-probably caused by constitutive repression of target gene transcription resulting from failure of the corepressor complex to dissociate from mutant TRβ. 5 Based on the homology (95%) of their thyroid hormone-binding domains, analogous mutations in human TRα had been predicted, 6 but only three diff erent frameshift-stop or prematurestop mutations within a TRα1-specifi c, carboxyterminalencoding exon have been described. [7] [8] [9] [10] However, mouse models with TRα1 mutations in other regions of the gene [11] [12] [13] [14] have been generated and have varying phenotypes, suggesting that molecular and clinical heterogeneity of the human disorder might be shown.
Here, we describe the fi rst family with a THRA defect resulting in mutation of both TRα1 and TRα2.
Methods
The index patient (patient 1, a 60-year-old woman) had features suggesting hypothyroidism at age 2 years (increased bodyweight, poor linear growth, constipation, and a large, prominent tongue), but her thyroid hormone concentrations were within the normal ranges. Nevertheless, she was treated with thyroxine-which improved her growth and constipation-and has continued to take the drug since.
Her eldest son (patient 2, age 30 years) was delivered by caesarean section because of macrocephaly. At age 6 weeks, he had to switch from breastfeeding to bottlefeeding to correct poor nutritional intake. His subsequent growth and developmental milestones (using a ball, speech) were delayed and-because his mother had had similar symptoms-he started thyroxine treatment at age 3 years, despite his thyroid hormone concentrations being within the normal ranges. Although his growth and development improved, his motor coordination remained poorcausing imbalance, clumsiness, and poor handwritingand he attended a specialist school for children with motor dyspraxia. He continued to take thyroxine throughout childhood and adulthood, except for an interval (26-29 years), during which time he noted constipation, weight gain, lethargy, and low mood. A second son (patient 3, age 26 years) was delivered by elective caesarean section. He had a large tongue and similar facial appearance to patient 2, and had drowsiness and delayed linear growth, speech and motor development, which improved after treatment with thyroxine from age 3 years. He also has signifi cant motor incoordination, for which he needed specialist schooling. A third son is unaff ected, with normal growth and development.
We took serial measurements of biochemical characteristics (thyroid function, sex-hormone-binding globulin, creatine kinase, lipids, bone turnover markers) and physiological characteristics (sleeping heart rate, resting energy expenditure) when patients were and were not taking thyroxine, as described previously, 7, 10 and compared these data with reference measurements from age and sex-matched people from a healthy volunteer cohort recruited by our clinical research facility. We did molecular genetic analysis of THRA and functional characterisation of mutant TRα1 and TRα2 (appendix). 7, 10 We compared diff erences in normal and mutant receptor function with a two-tailed t-test using Excel (version 14.3.9). We did structural modelling of mutant TRα1, TRα2 and TRβ proteins using MacPyMOL Molecular Graphics System (version 1.5.0.4). All investigations were part of an ethically approved protocol or were clinically indicated. All patients gave informed written consent.
Role of the funding source
The funders had no role in study design, collection, analysis or interpretation of the data, writing the report, or the decision to submit the report for publication. 
Results
All patients were taking thyroxine when referred, and were assessed both while taking treatment and 6 weeks after discontinuation. The patients had a broad face, fl attened nasal bridges, and prominent tongue (fi gure 1A have had their IQ properly tested, but that of patient 3 was low average (88) at school and all have achieved an A level educational qualifi cation (or equivalent). All patients had a thickened skull vault (cranial hyperostosis; fi gure 1C). Patient 1's bone mineral density T scores were slightly low at the hip (by dual-energy x-ray absorptiometry -1·0; by quantitative CT -1·7) and at the femoral neck (by quantitative CT -0·5), but normal at lumbar spine (+1·9). By contrast, patients 2 and 3 both had high bone mineral density T scores at these sites (by dualenergy x-ray absorptiometry patient 2: hip +0·8, lumbar spine +1·9; patient 3: hip +1·4, lumbar spine +1·9) and quantitative CT (patient 2: total hip +1·52 [94th centile for age], femoral neck +1·7 [96th centile for age]; patient 3: total hip +1·9 [97th centile for age], femoral neck +2·8 [99th centile for age]).
When not taking thyroxine, all patients had normal concentrations of thyroid-stimulating hormone (TSH). Patient 1 and patient 3 had marginally low and patient 2 had low-to-normal free thyroxine concentrations; patient 1 and patient 2 had normal and patient 3 had slightly high free tri-iodothyronine (T 3 ) concentrations (table) . However, all patients had a low ratio of thyroxine:T 3 (fi gure 1D), with subnormal concentrations of reverse T 3 (table) . Their resting energy expenditure was greatly reduced compared with healthy controls, with high concentration of skeletal muscle creatine kinase and mild, normocytic, anaemia (table) . Sequencing of THRA showed that the patients were heterozygous for a nucleotide substitution (GCG to GTG), corresponding to an alanine to valine change at codon 263 in the sequence common to both TRα1 and TRα2; the mutation segregates with abnormal phenotype and thyroid biochemistry, being present in the three patients but absent in unaff ected family members (sibling, father; appendix) and from normal genome databases (dBSNP, 1000 Genomes, NHLBI exome variant server).
Restriction fragment length polymorphism analysis and direct sequencing of TRα1 and TRα2 cDNAs derived from primary blood mononuclear cells from patient 1 confi rmed that Ala263Val mutant TRα1 and TRα2 mRNAs are coexpressed together with normal variant transcripts in vivo (appendix). Lack of antibodies that reliably distinguish between TRα1 and TRα2 subtypes, and between normal and mutant TRs, precluded testing for expression at the protein level. Wild-type TRα1 + Wild-type α2
Wild-type TRα1 + Ala263Val α2
Binding of the Ala263Val mutant TRα1 to radiolabelled T 3 was greatly reduced compared with normal receptor (appendix), consistent with structural modelling, which predicted that the Ala263Val substitution would impair T 3 binding to the receptor owing to steric hindrance (fi gure 2D). In transfection assays, Ala263Val mutant TRα1 had little eff ect on transcriptional activation of a thyroid hormone-responsive target gene at low concentrations of T 3 (0·001-10 nM; fi gure 2A), but at higher concentrations (100-10 000 nM) mutant receptor function was similar to that of normal receptor. Ala263Val mutant TRα1 was able to bind to DNA (fi gure 2A) and, when coexpressed with wild-type TRα1, it inhibited the transcriptional activity of its normal counterpart in a dominant-negative manner (fi gure 2B, appendix). High concentrations of T 3 (100 nM) reversed such inhibition in vitro and also reversed reduced expression of a thyroid hormone-responsive target gene (KLF9) in patient-derived peripheral blood mononuclear cells studied ex vivo (fi gure 2B, C). Consistent with reversal of dominant-negative inhibition by mutant TRα1 at high T 3 concentrations, higher (1000 nM) concentrations fully dissociated Ala263Val mutant TRα1 from a corepressor (NCoR) and recruited a coactivator (TRAP220) in assays that measured receptor interactions with cofactors (appendix). Ala263Val mutant TRα1 fails to dissociate from NCoR or to associate fully with TRAP220 at concentrations that would be suffi cient for normal receptor.
In comparison with its normal counterpart, the Ala263Val mutant TRα2 had similar cellular localisation, similarly negligible transcriptional function in either the absence or presence of T 3 , and similarly weak dominantnegative activity when overexpressed (fi gure 3).
After thyroxine treatment at a replacement dose (1·1-1·8 μg/kg), free thyroxine and free T 3 increased in all patients, TSH concentrations and circulating thyroglobulin concentrations fell. Total reverse T 3 concentration rose in patients 1 and 2 but was unchanged in patient 3 (table). Resting energy expenditure rose in all patients during treatment, but remained subnormal, with a smaller increase for patient 1, who takes lower doses of thyroxine (75 μg vs 150 μg). Concurrently, LDL-cholesterol concentrations fell in all patients (table). Creatine kinase concentration fell in patient 1 and patient 2, but increased in patient 3 (table). Many, but not all, markers of bone turnover increased, but sleeping heart rate changed little (table). All patients noted that their symptoms improved after restarting thyroxine: paraesthesiae suggestive of carpal tunnel syndrome resolved in patient 1, while both patient 2 and patient 3 reported reduced motor incoordination and constipation.
Discussion
The patients had many clinical features that suggest hypothyroidism (growth retardation, developmental delay, constipation, macrocephaly, large tongue), despite normal concentrations of circulating thyroid hormones. However, they had a subnormal free thyroxine:free T 3 ratio, low reverse T 3 concentration, high muscle creatine kinase concentration, and mild anaemia. The clinical and biochemical features of our patients are similar to the phenotype of patients with defective TRα1 alone, [7] [8] [9] [10] with no added characteristics attributable to any change to TRα2 function. Our observations accord with the absence of a phenotype linked specifi cally to TRα2 defi ciency in a knockout mouse line. 16 A patient with a diff erent, sporadic THRA mutation (asn359tyr) in both α1 and α2 subtypes, 17 had many dissimilar features (eg, clavicular agenesis, humeroradial synostosis, syndactyly, chronic diarrhoea, primary hyperparathyroidism), which are not present in TRα2 knockout mice, 16 and it is not clear whether these additional abnormalities are caused by the THRA mutation alone. 18 The alanine at codon 263 of TRα is highly conserved in diff erent species (fi gure 2E). The Ala263Val mutation is common to both TRα1 and α2, whereas previously described THRA mutations (glu403X, phe397fs406X, ala382PfsX7) are unique to TRα1. Three clusters of TRβ mutations (at amino acids 426-460, 309-353, and 234-282) are associated with resistance to thyroid hormone β and we have identifi ed a TRβ mutation (ala317val) analogous to the Ala263Val mutation in TRα1 that localises to one of these hotspots (fi gure 2E). The dysfunction of ala317val mutant TRβ resembles that of Ala263Val mutant TRα1, with severely reduced thyroid hormone binding, impaired thyroid hormone-dependent transcriptional activation, and dominant-negative activity that is reversible at high concentrations of T 3 (appendix). Structural modelling shows how T 3 binding might be impaired (appendix). This amino acid change involves a residue that has previously been reported mutated to threonine in patients with resistance to thyroid hormone, 19 and is within a recognised mutation cluster aff ecting the thyroid hormone-binding domain of TRβ in patients with this disorder (fi gure 2E).
The index patient with the ala317val TRβ mutation presented at age 4 years, with a thyroglossal cyst, high thyroid hormone concentration, and unsuppressed thyroid-stimulating hormone. Aff ected family members (mother and two siblings) had the same biochemical profi le, together with high reverse T 3 and thyroglobulin concentrations and these biochemical abnormalities segregate with heterozygosity for the ala317val mutation in TRβ (appendix). Each patient had features of resistance to thyroid hormone (proband: failure to thrive and increased appetite; sibling 1: frequent upper respiratory tract infections, hyperactivity, mild learning diffi culties, and increased appetite; sibling 2: failure to thrive) and their resting energy expenditure was high (proband: 142%; sibling 1: 152%; sibling 2: 122%; mother: 127%; normal: 95-105% of predicted values). The diff erences between patients with the ala317val mutation in TRβ and those with the Ala263Val mutation in TRα1 underscores the importance of TRβ for mediating negative feedback within the hypothalamo-pituitary-thyroid axis and TRα for mediating hormone action in the periphery (muscle, myocardium, gastrointestinal tract).
Our fi nding that the Ala263Val substitution inhibits binding of T 3 through steric hindrance provides a basis for the impaired hormone binding and transcriptional function of the Ala263Val mutant TRα1. By contrast, this aminoacid change is unlikely to have an eff ect on TRα2 function. Normal TRα2 does not bind T 3 , 20 is devoid of intrinsic transcriptional activity, and is a weak dominantnegative inhibitor of TRα1 function, 21, 22 perhaps because it interacts poorly with retinoid X receptor and corepressors, 22, 23 making additional loss-of-function as a result of the Ala263Val mutation unlikely. Conversely, although blocking phosphorylation of aminoacids at the TRα2 carboxyterminus induces dominant-negative inhibitory function, 24 the Ala263Val mutation is located outwith this domain.
Our patients had numerous skin tags and moles, which we have also noted in other patients with resistance to thyroid hormone caused by mutations in TRα1 (appendix). 9 Although present in the general population, the universal occurrence of this feature in people with defective TRα-even in childhood-suggests that it might be an additional characteristic of the disorder, although its absence would not exclude diagnosis. The enzyme DIO3 is present in human skin 25 and its expression is regulated by TRα1, 26 such that people with defective TRα might have diminished DIO3 activity. Topical inhibition of DIO3 activity enhances keratinocyte proliferation in mice 25 and we speculate that cutaneous DIO3 defi ciency in patients with defective TRα1 might mediate this phenotype. DIO3 defi ciency or upregulation of hepatic DIO1 (as suggested by studies of TRα1 mutant mice 12 ) might also mediate the low free thryoxine and high free T 3 concentrations, low ratios of free thryoxine:free T 3 and subnormal total reverse T 3 concentrations recorded in our patients.
Unlike previous reports of patients with highly deleterious TRα1 defects, 7, 8, 10 high concentrations of T 3 reversed Ala263Val mutant TRα1 dysfunction and dominant-negative activity in vitro. T 3 exposure restored subnormal expression of KLF9 in mutation-containing primary blood mononuclear cells, suggesting that dominant-negative inhibition by mutant TRα1 can also be overcome in vivo. We correlate these observations with improvement in some peripheral markers of thyroid hormone action (resting energy expenditure, creatine kinase) after thyroxine treatment; moreover, thyroid hormone treatment at physiological dose raised T 3 concentrations and suppressed TSH concentrations in patients 1 and 2, suggesting that the pituitary-thyroid axis is still sensitive to thyroid hormones in these patients.
Starting thyroxine treatment in childhood improved growth and development, and alleviated symptoms in adulthood without abnormally increasing concentrations of markers of bone turnover, as recorded previously. 10 In transgenic mice harbouring a mutant TRα1 (arg384cys) with ten-fold reduced binding affi nity towards T 3 , increased con centrations of thyroid hormones can reverse neuro logical abnormalities. 27 Neuro cognitive abnormalities might be less severe in these three patients because of early thyroid hormone treatment, but we cannot be certain of this possibility.
The identifi cation of patients with equivalent defects in TRα1 and TRβ tempts the speculation that other patients with TRα1 mutations might exist. Roughly 125 diff erent mutations in TRβ are known to cause resistance to thyroid hormone. 4, 5 Furthermore, maternal inheritance of the TRα mutation in this family, and paternal inheritance of the TRα mutation in another family, 8 suggests that transmission of TRα mutations from parents to off spring may not be as impaired in people as in mice. 12 With thyroid hormone con centrations being almost normal in patients with resistance to thyroid hormone caused by mutations in TRα, the clinical and biochemical characteristics of this family (together with features of previous cases) defi ne a phenotypic signature for this syndrome (panel). This signature should enable early identifi cation and treatment of other patients, which would be of particular importance should thyroxine treatment prove to be widely benefi cial for this disorder.
Panel: Research in context

Systematic review
We searched PubMed with the terms "THRA" and "mutation" for studies published in English between 2000 and 2014. Previously reported cases [7] [8] [9] [10] of resistance to thyroid hormone caused by THRA mutations involve mutations that selectively disrupt thyroid hormone receptor (TR)α1 function, manifesting with typical features of hypothyroidism but paradoxically near-normal circulating thyroid hormone concentrations. A patient described in an abstract 17 had some hypothyroid features and near-normal hormone concentrations, but also many dissimilar characteristics that may not be caused by the THRA defect.
Interpretation
We describe the fi rst patients with a mutation common to TRα1 and the variant TRα2 protein derived from the same gene. Their clinical (growth and developmental retardation, constipation, macrocephaly) and biochemical features (subnormal ratio of free thyroxine:free tri-iodothyronine [T 3 ], low reverse T 3 ) are similar to previous patients with resistance to thyroid hormone caused by mutation in TRα1, with no added phenotype attributable to the presence of mutant TRα2. T 3 reverses mutant receptor dysfunction in vitro and thyroxine therapy alleviates hormone resistance in vivo; starting treatment with thyroxine in childhood might have ameliorated their clinical phenotype. Future identifi cation of other patients, based on common characteristics of these and previous patients that now defi ne the syndrome, will be of clinical importance if early thyroxine treatment proves to be widely benefi cial.
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